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Abstract 
Background: Recent epidemics of highly pathogenic avian influenza (HPAI) produced an unprecedented number 
of cases in mute swans (Cygnus olor) in European countries, which indicates that these birds are very sensitive to the 
H5N1 virus. The HPAI outbreaks stirred a debate on the controversial stamping-out policy in populations of protected 
bird species. After preventive vaccination had been approved in the European Union, several countries have intro-
duced vaccination schemes to protect poultry, captive wild birds or exotic birds in zoos against HPAI. The aim of this 
study was to investigate the immune response of wild mute swans to immunization with an inactivated AI H5N2 vac-
cine approved for use in poultry. The serological responses of mute swans were assessed by comparison with racing 
pigeons (Columba livia), a species which is characterized by different susceptibility to infection with the H5N1 HPAI 
virus and plays a questionable role in the ecology of influenza (H5N1) viruses.
Results: Swans were vaccinated once or twice at an interval of 4 weeks. The humoral immune response was evalu-
ated by hemagglutination inhibition (HI) and NP-ELISA. The lymphocyte blast transformation test was used to 
determine the cell-mediated immune response. Higher values of the geometric mean titer (GMT) and 100 % serocon-
version (HI ≥32) were noted in double vaccinated swans (1448.2) than in single vaccinated swans (128.0) or in double 
vaccinated pigeons (215.3). Significant differences in HI titers were observed between swans and pigeons, but no 
variations in ELISA scores were noted after the booster dose. Immunization of swans had no effect on the proliferative 
activity of lymphocytes.
Conclusions: The inactivated H5N2 vaccine was safe and immunogenic for mute swans and pigeons. Vaccination 
may have practical implications for swans kept in zoos, wildlife parks or rehabilitation centers. However, challenge 
studies are needed to prove the efficacy of the H5N2 AI vaccine.
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Background
Mute swans (Cygnus olor, Gm. 1789) of the order Anseri-
formes and other wild birds of the orders Anseriformes 
and Charadriiformes are important natural reservoirs 
of low pathogenic avian influenza (LPAI) viruses. LPAI 
viruses of subtypes H5 and H7 can evolve into HPAI 
(highly pathogenic avian influenza) viruses once intro-
duced into poultry. In contrast to LPAIV, HPAI viruses are 
rarely detected in wild birds [1–4]. The first known report 
discussing the possible role of swans in the epidemiol-
ogy of avian influenza was dedicated to whistling swans 
in Japan [5]. Following a massive HPAI outbreak in wild 
geese in 2005, the Qinghai-like HPAI virus H5N1 (clade 
2.2) continued to spread across three continents, resulting 
in devastating losses in the poultry industry. Mute swans 
were the most frequently affected species of wild birds, 
particularly in Europe [3, 6–8]. Subsequent investigations 
revealed the sensitivity of swans to infections and varia-
tions in the pathobiology of the HPAI H5N1 virus [3, 7, 9]. 
Several studies have demonstrated that mute swans could 
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be vectors of HPAI H5N1 over short distances, and that 
they represent a new avian host in HPAI virus ecology [6, 
7]. Mute swans were recognized as a source of infection 
in the first global cases of HPAI H5N1 infections passed 
by birds to humans [10]. Further studies demonstrated 
that the opportunities for swan-to-human transmission 
of H5N1 were extremely rare [11]. In AI surveillance 
programs, mute swans were an effective indicator spe-
cies (sentinel birds) in the epidemiology of HPAI [3, 7]. 
Since 2010, HPAI H5N1 viruses have become enzootic 
and evolved dynamically to form multiple H5 HA clades 
[4, 12]. Between 2014 and 2015, various HPAIV H5 sub-
types of several clades have spread rapidly and globally in 
poultry and wild birds [12, 13]. Furthermore, mute swans 
(Sweden 2015) and other swan species were affected by 
the novel reassortant H5N8 virus [8].
Unlike swans, pigeons were long regarded as a species 
that is highly resistant or minimally susceptible to infec-
tion with HPAIV [14–16]. However, according to the 
recent literature, pigeons’ susceptibility to H5N1 virus 
and their role in AI epidemiology have been questioned 
[16, 17]. Avian influenza is still an unsolved problem 
for the racing pigeon industry, mainly due to a lack of 
detailed regulations. The restrictions put on poultry in 
connection to suspected and confirmed HPAI outbreaks 
also apply to domestic pigeons. Thus vaccination may be 
a solution to avian influenza problem in racing pigeon 
industry.
The global strategy for the control and eradication of 
HPAI involves strict administrative procedures, includ-
ing confinement, stamping-out and pre-emptive culling 
[18, 19]. The application of radical solutions to healthy, 
valuable, endangered and protected species of birds (held 
in captivity) was met with high opposition for ethical, 
social, and environmental reasons [20]. Pursuant to the 
provisions of Council Directive 2005/94/EC, AI vaccina-
tion was approved in EU as an additional measure dis-
ease control and an alternative to pre-emptive culling. 
The vaccination strategy should be carried out only in 
combination with biosecurity measures [21–23]. In the 
EU, commercial inactivated AI vaccines were licensed 
for use only in chickens and Pekin ducks, but they were 
also shown to be effective in other bird species [24–26]. It 
should be noted that only individual species of wild birds 
kept in captivity can be considered for AI vaccination. 
Many studies demonstrated that vaccine-induced anti-
body responses in birds were determined by the species, 
vaccine type or dose [25, 27]. However, little is known 
about vaccination of swans and pigeons against HPAI 
H5N1 [26, 27, 42, 48].
In view of the above, the aim of this study was to evalu-
ate the immune response of mute swans immunized 
against AI with an inactivated vaccine. The serological 
response of swans was compared with that of racing 
(domestic) pigeons (Columba livia f. domestica) immu-
nized with the same vaccine. Pigeons were compared 
with mute swans based on differences in the susceptibil-
ity of the two species to H5N1 HPAIV.
Methods
Mute swans
Eleven free-living mute swans were captured in early 
spring in central Poland. Immature swans of both sexes 
(2-year-old males n = 4, 36.4 %; females n = 7, 63.6 %) 
were marked with ornithological rings and transported 
to the Agricultural Experiment Station of the Warsaw 
University of Life Sciences. They were placed in indi-
vidual boxes and exposed to the natural light–dark cycle. 
Feed and water were provided ad libitum.
Vaccine
Birds were immunized with the Nobilis® Influenza H5N2 
vaccine based on an inactivated, whole avian influ-
enza virus (A/duck/Potsdam/1402/86, European strain) 
inducing an HI titer of  ≥6.0 log2 (MSD Animal Health, 
Boxmeer, Netherlands). The vaccine strain has 90  % 
nucleotide sequence homology to the HA gene of the 
H5N1 HPAI field strain A/turkey/Turkey/1/05; clade 2.2 
(1530 base pairs, including basic cleavage site), and 92.4 % 
homology based on the amino acids sequence [30]. The 
vaccine was chosen based on its specific subtype, avail-
ability, licensing considerations, safety and efficacy data 
for poultry and other birds, and DIVA (Differentiating 
Infected from Vaccinated Animals) guidelines [18, 28–
30]. The Nobilis® Influenza H5N2 vaccine is commercially 
available and has been approved by the European Com-
mission and the European Medicines Agency [31].
Experimental design
Vaccination of mute swans
Mute swans were divided into two experimental groups 
(D1, D2, n = 8) and one control group (C, n = 3). Each 
group contained birds of both sexes: D1 (n  =  4): 1 
male and 3 females; D2 (n = 4): 2 males and 2 females; 
C (n  =  3): 1 male and 2 females. Birds were manually 
restrained for vaccine administration. Group D1 swans 
were vaccinated once (day 0). Swans from group D2 were 
vaccinated twice: on day 0 and 4  weeks later (4-week 
interval). The dose was adjusted for body weight. Birds 
were given a dose of 1 ml. The vaccine was administered 
subcutaneously to the nape of the neck. The control 
group was not vaccinated.
Vaccination of racing pigeons for comparative analysis
Four young racing pigeons aged 3–12 months were vacci-
nated twice according to the schedule for D2 mute swans. 
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The vaccine was administered subcutaneously in the dor-
sal region of the neck. Each pigeon (body weight >400 g) 
received a dose of 0.5 ml. Pigeons were kept at the Small 
Animal Clinic of the Faculty of Veterinary Medicine at 
the Warsaw University of Life Sciences (SGGW). They 
were placed in individual cages (450  mm  ×  900  mm) 
with ad  libitum access to water and feed, temperature 
of 22–25  °C and humidity of 50–70  %. The birds were 
exposed to 10 h of light per day.
Safety monitoring
During the study, swans and pigeons were observed twice 
daily and were weighed before the first vaccine adminis-
tration and then every 7 days. After immunization, vac-
cine tolerance and any side effects, in particular localized 
reactions at the injection site, were recorded. Birds were 
also observed for adverse effects [25].
Serological tests
Blood samples from the medial metatarsal vein were col-
lected 5 times: before the first vaccination (0) and in weeks 
2, 4, 6, and 8. At these dates, the presence of H5 subtype-
specific antibodies in serum samples was determined by 
the hemagglutination inhibition test (HI). The HI test 
was performed according to standard procedures using 4 
HAU of commercially available H5 heterologous antigen 
(A/chicken/Belgium150/99soncke99/150v6, H5N2) (GD 
Animal Health, Deventer, the Netherlands). HI titers were 
expressed in log2, where 4 log2 (HI ≥16) was the minimum 
positive titer [15, 23]. The geometric mean titer (GMT), 
seroconversion (SR) and protection rates (PR) were deter-
mined with the use of methods described in previous stud-
ies [25, 27, 32]. According to Bertelsen et al. [32] the SR and 
PR were expressed as the percentage of birds with titers 
higher than or equal to 16 and 32, respectively. Similarly to 
other authors, we assumed for the purpose of this study a 
HI titer ≥32 could be considered protective [25, 32].
The presence of AI type-specific antibodies was 
determined by NP (nucleoprotein)–blocking ELISA 
(FlockChek AI MultiS-Screen Ab Test Kit, IDEXX Lab-
oratories, Inc., Westbrook, Maine USA). ELISA results 
were analyzed using xChek® ver. 3.3 software (IDEXX 
Laboratories, Inc., Westbrook, Maine USA). The mean 
S/N ratio (sample to negative control ratio) and coeffi-
cient of variation (% CV, standard deviation divided by 
the mean) were presented. The S/N cut-off was set at <0.5 
to identify antibody-positive samples.
Before vaccination (day 0), serum samples were exam-
ined for the presence of NDV antibodies in the HI test 
to reduce the risk of possible cross-reactions and false 
positive results. The NDV antigen, LaSota strain (GD 
Animal Health, Deventer, the Netherlands) was used in 
HI [23, 29].
Evaluation of cell‑mediated immunity by the Lymphocyte 
Blast Transformation Test
Lymphocytes from heparinized peripheral blood sam-
pled from swans were separated by the gradient centrifu-
gation method using Gradisol L (Aqua-Med, Poland) and 
were washed in supplemented Eagle’s medium (Biomed 
Lublin, Poland). Cells were adjusted to 2.0  ×  106 cells/
ml in Eagle’s medium with fetal calf serum, and 100  µl 
from each well was transferred to 96-well plates. Lym-
phocyte cultures were stimulated by two non-specific 
T cell mitogens: phytohemagglutinin (PHA) and conca-
navalin A (ConA) (Sigma-Aldrich, USA), as well as a spe-
cific stimulator: inactivated AIV H5 antigen (A/Chicken/
Belgium150/99, LPAI H5N2). Each mitogen (100 µl) was 
added in triplicate at a final concentration of 5.0, 2.5 and 
1.25  µg/ml for PHA and ConA and with HA activity of 
1/8 and 1/16 for Ag H5. The cultures were incubated 
for 72 h at 41  °C. Radiolabeled 3H-thymidine (40 MBq/
ml) (Lacomed, Czech Republic) was added for the final 
incubation of 24 h at 41 °C. Controls included unstimu-
lated labeled and unlabeled cells. The general procedure 
was adopted based on the literature [33–35]. After incu-
bation, the cells were deposited on glass fiber discs with 
a cell harvester (Skatron, Norway), and the amount of 
incorporated radioactivity was measured with the Wal-
lac 1414 WinSpectral liquid scintillation counter (Perki-
nElmer Life Sciences, Wallac Oy, Turku, Finland). T-cell 
proliferative activity was expressed by the stimulation 
index (SI). Proliferation was regarded as significant at 
SI ≥2 [36].
Virus isolation
Before vaccination, cloacal swabs from swans and pigeons 
were collected in tubes containing a liquid medium: 
sterile phosphate buffered saline—PBS (BIOMED, Lub-
lin, Poland) with an antibiotics (Antibiotic Antimycotic 
Solution 100×  , Sigma, USA). Clarified supernatant flu-
ids from swabs were inoculated (0.2 ml) in embryonated 
11-day-old chicken eggs. The eggs were incubated at 
37  °C for 72  h and candled daily. Amnio-allantoic fluid 
was harvested and tested in the hemagglutination assay 
(HA). HA-negative samples (derived from swans) were 
passaged three times using undiluted amnio-allantoic flu-
ids as inoculum. One passage was performed for samples 
derived from pigeons. Three eggs per sample were used 
in every passage [23, 29].
Molecular tests
RNA was isolated from amnio-allantoic fluids and cloacal 
swabs using the QIAamp Viral RNA Mini Kit (Qiagen, 
Germany). The presence of AIV was tested by matrix 
(M) gene-based Real-Time RT-PCR using the OneStep 
RT-PCR Kit (Qiagen, Germany) [37]. For more specific 
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detection of the H5 subtype (including Eurasian isolates), 
the H5 gene was amplified by Real-Time RT-PCR and RT-
PCR [38, 39]. The presence of NDV was checked by RT-
PCR [40]. Two inactivated H5N1 antigens (A/whooper 
swan/Germany/R65-2/06, A/turkey/England/250/07) 
and the NDV antigen were used as positive controls.
Statistical analysis
The results were processed in Statistica 10.0 software. 
Group means were compared by the t-test for variables 
with normal distribution and in the Mann–Whitney 
U test for other distributions. Three or more groups of 
variables were compared against normal distribution by 
one-way analysis of variance for completely randomized 
or repeated measures and Fisher’s multiple comparison 
procedure. The Kruskal–Wallis test was used to compare 
non-normal distributions. The results were expressed 
as arithmetic means and standard deviation (SD). Geo-
metric means were calculated for selected variables. The 




Mute swans and pigeons showed no clinical signs of 
disease before vaccination. All swans were in good 
health, and their average body weight was determined 
at 8.3  ±  1.2  kg (8.8  ±  0.5  kg in males, 8.0  ±  1.4  kg in 
females).
No adverse effects were observed. The final body 
weight of the swans decreased by 1.1 kg during the study 
period, but the differences in the average body weight of 
experimental and control group birds were not statisti-
cally significant (P  >  0.05). The behavior of vaccinated 
swans did not differ from that of control swans. Cases of 
mortality or injuries due to handling, catching and man-
ual restraint were not observed.
Serological tests
Before vaccination (day 0), swans and pigeons tested 
seronegative for AIV/H5 in HI and NP-ELISA. The unvac-
cinated control remained seronegative throughout the 
entire 8-week experiment. Serum samples tested before 
the experiment, gave negative results for NDV in HI.
Post‑vaccination HI titers in mute swans
Vaccine antibody responses in the HI test are shown in 
Fig.  1a. Statistically non-significant (NS) differences 
were found between groups in week 0. In weeks 2, 4, 6 
and 8, the mean log2 HI titers in D1 and D2 birds were 
significantly higher (P < 0.01) than in the control group. 
Beginning from week 2, highly significant differences 
(P < 0.01) in HI titer values were observed in groups D1 
and D2. However, 25 % of vaccinated swans were nega-
tive in the HI test two weeks after the administration of 
the first dose. Four weeks after the first vaccination the 
overall GMT was 152, and SR (HI ≥  16), PR (HI ≥  32) 
reached for the first time 100 %. After the administration 
of the booster dose, antibody titers in group D2 increased 
significantly by 2.5 log2 and were higher (P < 0.01) than 
in group D1. The highest antibody titers were noted in 
weeks 6 and 8 in groups D1 (7.0 log2) and D2 (10.5 log2). 
At the end of study (week 8), GMT was approximately 
11-fold higher (GMT 1448.2) in swans administered a 
booster vaccine than in swans that were vaccinated only 
once (GMT 128.0). In week 8, SR and PR reached 100 % 
(HI ≥ 16 and ≥ 32) in D1 and D2 swans. No statistically 
significant differences were found in group C during the 
study.
Post‑vaccination HI titers in racing pigeons
The results of the HI assays are shown in Fig.  1b. The 
titers were positive between week 2 (after the first vac-
cine dose) and the end of the experiment. In week 4, the 
overall GMT was determined at 45.3, and SR reached for 
the first time 100 %. The earliest sampling point when PR 
reached 100  % was two weeks after booster dose (week 
6). The highest antibody titer in pigeons (8.0 log2), 100 % 
SR and PR were noted in week 8. Significant differences 
(P  <  0.05) in log2 HI titer values between pigeons and 
swans were noted in weeks 2 and 6, whereas highly sig-
nificant differences (P < 0.01) were observed in weeks 4 
and 8. In general, antibody titers in D2 swans were higher 
(P < 0.05) than in pigeons after the first and second vac-
cination. No significant differences were found between 
groups at week 0.
ELISA results in mute swans
The results of the NP-ELISA are shown in Fig.  2a. No 
differences were found between the groups in week 0. 
After vaccination, highly significant differences (P < 0.01) 
were noted in S/N values in groups D1, D2 relative to the 
values noted before vaccination and the control group. 
In weeks 2, 4, 6 and 8, highly significant differences 
(P  <  0.01) in the S/N ratio were noted between C, D1 
and D2, whereas no significant differences were observed 
between D1 and D2. The mean S/N values after the first 
vaccination were determined at 0.106, CV 48.8 % (week 
2) and 0.082, CV 24.2 % (week 4). The mean S/N values in 
group D1 reached 0.110 (CV 45.5 %) in week 6 and were 
somewhat higher in week 8 (S/N 0.126, CV 52.4 %). The 
booster dose induced a minor decrease in S/N to 0.066 
(CV 13.4 %) in group D2 in week 6. In group D2, S/N val-
ues were determined at 0.070 (CV 10.9 %) in week 8. Sta-
tistically non-significant (NS) differences were found in 
group C during the study.
Page 5 of 9Dolka et al. Acta Vet Scand  (2016) 58:74 
ELISA results in racing pigeons
Vaccinated pigeons tested positive for NP antibodies in 
ELISA (Fig.  2b). After the first vaccination, S/N values 
were determined at 0.488 (CV 20.8) in week 2, 0.321 (CV 
48.6 %) in week 4, and they were significantly higher than in 
swans (P < 0.01 in week 2 and P < 0.05 in week 4). After the 
administration of the booster vaccine, the lowest S/N value 
(0.115, CV 53.9  %) was observed in week 8. A tendency 
towards higher S/N values was not observed in pigeons (in 
weeks 2, 4, 6 and 8). Statistically non-significant differences 
in S/N values were found between swans and pigeons (in 
weeks 6 and 8) after the second vaccine dose.
Lymphocyte blast transformation test
The results of the lymphocyte blast transformation test 
showed no difference between control and vaccinated 
animals (Table 1).
Virus isolation
Amnio-allantoic fluids from eggs inoculated with the 
medium from cloacal samples collected before vaccina-
tion, produced negative results in the HA test.
Molecular tests
All samples (cloacal swabs and amnio-allantoic fluids 
from eggs inoculated with the medium from cloacal sam-
ples) tested negative for AIV in Real-Time RT-PCR (M 
gene-based) and in the H5 subtype-specific PCR assays. 
NDV RNA was not detected by RT-PCR.
Discussion
Several schedules of AI vaccination for exotic birds have 
been proposed [41–44], but specific antibody titers with 
confirmed protective levels for mute swans and racing 
pigeons have not yet been identified. The present study 
was carried out to analyze the immune responses of wild 
mute swans vaccinated with an inactivated AI H5N2 vac-
cine licensed for use in chickens in the EU. To the best 
Fig. 1 a Mean log2 HI titers against the H5N2 antigen in control (C) 
and vaccinated mute swans (D1, D2). b Mean log2 HI titers against the 
H5N2 antigen in mute swans (group D2) and racing pigeons. Inter-
pretation: HI ≥ 4 log2 (16) positive, HI < 4 log2 (16) negative. Small 
letters (a, b, c) denote significant differences in log2 HI titers between 
groups in successive weeks based on the results of the Kruskal–Wal-
lis test. Capital letters (A, B, C) denote significant differences in log2 HI 
titers between weeks (0, 2, 4, 6, 8) within groups based the results of 
the on Kruskal–Wallis test
Fig. 2 a Mean values of the S/N ratio in ELISA for control and vacci-
nated mute swans (groups C, D1, D2). b Mean values of the S/N ratio 
in ELISA for mute swans (group D2) and racing pigeons. Interpreta-
tion: cut-off: S/N = 0.5, S/N < 0.5 positive, S/N ≥ 0.5 negative. Small 
letters (a, b) denote significant differences in the values of the S/N 
ratio between groups in successive weeks based on the results of 
Fisher’s multiple comparison procedure. Capital letters (A, B) denote 
significant differences in the values of the S/N ratio between weeks 
(0, 2, 4, 6, 8) within groups
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of our knowledge, this is the first study to investigate the 
serological responses induced by AI vaccination in mute 
swans. The antibody response of swans was compared 
with that of racing pigeons.
According to the literature, inactivated H5N2 vaccines 
are well tolerated by domestic waterfowl and zoo birds 
[25, 41]. The vaccine used in the present study was safe 
for swans and pigeons. Our findings corroborate the 
results of studies which demonstrated that AI vaccines 
approved for use in poultry induced an immune response 
in non-target avian species [27, 30, 41]. Other authors 
noted 100  % SR in Anseriformes or in black swans after 
the first dose of an inactivated H5N2 vaccine [41, 44]. In 
this study, seroconversion was not observed in all swans 
after the first vaccination, which could point to variations 
in early response. Our results are in agreement with the 
findings of other authors who demonstrated differences in 
immune responses within the same bird species [32, 41, 
45]. In our study, the overall GMT in mute swans after 
the first dose was higher than the known GMT values for 
black swans and other Anseriformes [26, 41, 44, 45], and 
it was lower than reported in Accipitriformes, Phoenicop-
teriformes [27, 44]. Based on the literature, the differences 
induced by vaccination are observed between and within 
taxonomic orders. It could be assumed that single dose of 
the vaccine may induce relatively high antibody titers in 
mute swans. However, the type of H5 vaccine strain may 
have impact on the antibody responses [25, 27, 30].
Similarly to other studies, the effect of a booster dose 
was clearly demonstrated in this study [22, 25, 42, 44]. 
High seroconversion (100  %) was induced by booster 
dose of an inactivated H5N2 vaccine in black swans and 
other Anseriformes [41, 44], whereas lower seroconver-
sion was also reported [27]. We observed dissimilar 
kinetics of the anti-NP and anti-HA antibodies after vac-
cination. The differences in NP-ELISA scores between D1 
and D2 were not statistically significant throughout the 
study (week 2, 4, 6, 8). The findings indicate, that booster 
dose of vaccine did not have a significant impact on the 
increase of anti-NP titers, in contrast to anti-HA titers. 
The results highlight the role of anti-HA antibodies in the 
immune response to AI vaccination.
Table 1 In vitro proliferative responses (SI ±  SD) of  peripheral blood lymphocytes after  stimulation with  PHA, ConA 
mitogens and H5 antigens in mute swans from control and experimental groups (C, D1, D2)
NS no statistically significant differences based on analysis of variance and Fisher’s multiple comparisons in SI between weeks and groups for a given mitogen
Mitogen concentrations [µg/ml]  
or antigen (HA titer)
WeekNS SI ± SD values in groups of mute swansNS
C D1 D2
PHA 5.0 µg/ml 0 1.29 ± 0.13 0.68 ± 0.78 1.31 ± 1.10
4 0.90 ± 0.06 1.26 ± 0.18 0.96 ± 0.13
8 1.22 ± 0.06 1.20 ± 0.36 1.20 ± 0.09
PHA 2.5 µg/ml 0 1.14 ± 0.13 0.77 ± 1.02 1.43 ± 0.33
4 1.16 ± 0.23 0.55 ± 0.14 0.90 ± 0.62
8 1.41 ± 0.09 1.73 ± 0.38 1.53 ± 0.16
PHA 1.25 µg/ml 0 1.59 ± 0.44 1.5 ± 0.58 1.88 ± 0.28
4 1.26 ± 0.36 1.01 ± 0.18 1.21 ± 0.74
8 1.17 ± 0.86 2.41 ± 1.49 1.09 ± 0.34
ConA 5.0 µg/ml 0 1.27 ± 0.18 1.46 ± 0.06 1.74 ± 0.59
4 0.92 ± 0.07 1.98 ± 1.02 1.21 ± 0.34
8 1.14 ± 0.11 1.26 ± 0.45 1.84 ± 0.51
ConA 2.5 µg/ml 0 1.44 ± 0.33 1.85 ± 0.46 1.67 ± 0.51
4 1.02 ± 0.16 2.18 ± 1.08 1.58 ± 0.91
8 1.70 ± 0.37 1.86 ± 0.63 3.16 ± 1.46
ConA 1.25 µg/ml 0 1.82 ± 0.26 1.41 ± 0.14 1.15 ± 0.48
4 1.06 ± 0.18 0.99 ± 0.64 1.29 ± 0.67
8 1.93 ± 0.87 1.69 ± 0.00 3.17 ± 1.51
H5 (HA 1/8) 0 0.96 ± 0.05 1.29 ± 0.09 0.80 ± 0.58
4 1.01 ± 0.07 0.56 ± 0.25 0.90 ± 0.00
8 1.24 ± 0.22 1.18 ± 0.42 1.2 ± 0.15
H5 (HA 1/16) 0 1.04 ± 0.38 0.83 ± 0.43 1.03 ± 0.46
4 0.77 ± 0.10 0.45 ± 0.20 0.79 ± 0.00
8 1.27 ± 0.26 1.60 ± 0.81 1.31 ± 0.11
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Elevated GMT in mute swans supported the observa-
tions made in black-necked swans, coscoroba swans and 
trumpeter swans, but differed from the values reported 
in whistling swans where GMT was low [30]. The H5N2 
vaccine used in this study and H5N9 vaccines induced 
lower overall GMT and seroconversion in different spe-
cies of Anseriformes than in mute swans [26, 27, 30, 32]. 
However, the differences in HI titers can be attributed to 
species-specific factors, vaccination schedules or differ-
ences in HI assays.
A clear relationship between HI titers and protec-
tion against AIV of the same HA subtype [2, 22] was 
reported in chickens, but it was not noted in mute 
swans. Studies of ducks demonstrated that vaccines 
characterized by high protein homology of HA1 with 
the challenge strain (89–100  % of amino acid simi-
larities) delivered the best protection results [46]. This 
study relied on the assumption that vaccination in 
mute swans would produce similar results. The strains 
of HPAI viruses subtype H5N1 circulating at that time 
in Poland belonged to clade 2.2 [15]. Based on the high 
percentage (90–92.4  %) of homology of the vaccine 
strain with strains H5N1 (clade 2.2), we suggested that 
both antigenic and genetic distance between vaccine 
strain and circulating field strains in Poland can be con-
sidered the same (or very similar). Antigenically drifted 
avian influenza viruses decreased the effectiveness of 
commercial poultry vaccines, but not all antigenic vari-
ants of HPAIV H5N1 evaded vaccine-induced immunity 
in birds [46, 47]. Some studies revealed that genetically 
more distant vaccines could protect ducks against infec-
tion with H5N1 viruses [46]. In our study, a potent anti-
body response was observed in mute swans, but its role 
in conferring immunity against heterologous viruses 
needs to be further investigated.
In this study, booster vaccination was needed for all rac-
ing pigeons to produce titers of  ≥32. The overall GMT 
was similar to that of rock pigeons vaccinated with the 
H5N6 vaccine [48], but was lower than obtained by H7N1 
vaccine [42]. Unlike in this experiment, the same H5N2 
vaccine induced lower antibody titers and seroconversion 
in Columbiformes [27, 30]. In this study, species-specific 
differences in vaccine-induced antibody titers were noted 
between mute swans and racing pigeons. The overall 
GMT in pigeons was approximately sevenfold lower than 
in swans. Our findings are consistent with the results 
reported in Anseriformes which developed stronger 
immune responses to inactivated vaccines than Columbi-
formes [26, 30, 48]. Selected species-specific factors, such 
as the role played by a given species in avian influenza epi-
demiology, AIV ecology and its susceptibility to HPAIV 
infection, could influence  on the vaccine-induced anti-
body titers.
In our study, the vaccine promoted the development of 
both subtype H5 and type A influenza specific antibodies 
(anti-NP antibodies) in swans and pigeons. The significance 
of the antibody response to NP-induced by vaccination has 
not been fully elucidated. Anti-NP antibodies are not neu-
tralizing, but according to recent reports, they could play a 
role in the promotion of cellular immunity [49].
Immunization of mute swans had no effect on the pro-
liferative activity of lymphocytes. Our results were in 
agreement with data demonstrating that immunization 
of ducks with an inactivated vaccine did not increase the 
cellular response [34, 36]. Higgins et  al. [34] suggested 
that ducks could have detectable levels of serum anti-
bodies when the cell-mediated immune response is not 
detected in the lymphocyte transformation test. Further 
research into cellular immune responses in Anseriformes 
is needed to validate this hypothesis.
Conclusions
The present study demonstrated that immunization of 
mute swans with an inactivated H5N2 vaccine is safe and 
induced a strong humoral immune response. Humoral 
responses in swans were higher than in pigeons, but the 
induced antibody titers exceeded the levels presumed 
to confer immunity in poultry [2, 25, 27, 32]. A booster 
dose is recommended to enhance and maintain antibody 
titers. Our results could have practical implications for 
vaccination strategies for captive swans in zoos, wildlife 
parks or rehabilitation centers. Under extraordinary cir-
cumstances, vaccination of racing pigeons may be a use-
ful strategy to save these birds from indoor confinement 
and pre-emptive culling (especially valuable individuals) 
due to the potential risk of AI outbreak. It could allow 
to continue the long-term breeding work and thus avoid 
economic losses. The challenge studies are needed to 
prove the efficacy of the H5N2 AI vaccine, in particular 
against the new H5 virus variants, and to formulate con-
clusive recommendations for immunization.
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